IOL Chemicals and Pharmaceuticals Limited announced its audited financial results for the quarter ended 31st March 2026, alongside the board’s decision to approve the installation of a new manufacturing plant for “Triacetin” (with an installed capacity of 6000 MTPA) and the expansion of its “Pantoprazole” manufacturing capacity from 240 MTPA to 276 MTPA, both funded via internal accruals. For the quarter ended 31st March 2026, the company reported revenue from operations of Rs 619.45 crore, compared to Rs 580.39 crore in the previous quarter (31st December 2025) and Rs 527.78 crore in the corresponding quarter of the previous year (31st March 2025). The following table summarizes the comparative financial performance:

Note: As per the audited results, the company’s profit after tax for the year ended 31st March 2026 was Rs 101.07 crore.

IOL Chemicals and Pharmaceuticals Limited, established in 1986 and headquartered in Barnala, Punjab, is a leading global player in the Active Pharmaceutical Ingredients (API) and specialty chemicals sectors. The company is recognized as a dominant manufacturer of Ibuprofen, holding a significant global market share, and has expanded its portfolio to include various pharmaceutical intermediates and specialty chemicals. In early 2026, the company sought to streamline its corporate structure by filing an application to strike off its dormant, wholly-owned subsidiary, IOL Life Sciences Limited. The company continues to focus on regulated market expansion and capacity optimization for its new paracetamol facility, which has shown steady progress in capacity utilization.

The company’s recent performance reflects a strategic focus on volume recovery in non-Ibuprofen APIs and cost-efficiency measures, despite past margin pressures from elevated fuel costs. As of March 2026, the promoter group holds a 57.48% stake in the company, with notable corporate shareholders including Maya Devi Polycot Limited (21.79%), Nm Merchantiles Limited (17.08%), and Ncvi Enterprises Limited (16.58%). The company’s consistent focus on internal accruals for funding its capital expenditure projects, such as the new Triacetin and Pantoprazole capacity expansions, underscores its commitment to organic growth without equity dilution.